Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2) von Burger, H, Zoumaro‐Djayoon, A, Boersma, AWM, Helleman, J, Berns, EMJJ, Mathijssen, RHJ, Loos, WJ, Wiemer, EAC

Volltext

The VEGF pathway and the AKT mTOR p70S6K1 signalling pathway in human epithelial ovarian cancer von Trinh, X B, Tjalma, W A A, Vermeulen, P B, Van den Eynden, G, Van der Auwera, I, Van Laere, S J, Helleman, J, Berns, E M J J, Dirix, L Y, van Dam, P A

Volltext

TP53 and ovarian cancer von Schuijer, Monique, Berns, Els M.J.J.

Volltext

Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling von JANSEN, Maurice P. H. M, FOEKENS, John A, KLIJN, Jan G. M, BERNS, Els M. J. J, VAN STAVEREN, Iris L, DIRKZWAGER-KIEL, Maaike M, RITSTIER, Kirsten, LOOK, Maxime P, MEIJER-VAN GELDER, Marion E, SIEUWERTS, Anieta M, PORTENGEN, Henk, DORSSERS, Lambert C. J

Volltext

Molecular profiling of platinum resistant ovarian cancer von Helleman, Jozien, Jansen, Maurice P.H.M., Span, Paul N., van Staveren, Iris L., Massuger, Leon F.A.G., Meijer‐van Gelder, Marion E., Sweep, Fred C.G.J., Ewing, Patricia C., van der Burg, Maria E.L., Stoter, Gerrit, Nooter, Kees, Berns, Els M.J.J.

Volltext

Abstract P5-08-51: SIAH2 protein expression is inversely correlated with the ER status and outcome to tamoxifen therapy in metastatic breast cancer patients von van der Willik, KD, Timmermans, MM, Look, MP, Reijm, EA, van Deurzen, CHM, den Bakker, MA, Westenend, PJ, Martens, JWM, Berns, EMJJ, Jansen, MPHM

Volltext

Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer von Reijm, E. A, Jansen, M. P. H. M, Ruigrok-Ritstier, K, van Staveren, I. L, Look, M. P, van Gelder, M. E. Meijer, Sieuwerts, A. M, Sleijfer, S, Foekens, J. A, Berns, E. M. J. J

Volltext

A Common Polymorphism Renders the Luteinizing Hormone Receptor Protein More Active by Improving Signal Peptide Function and Predicts Adverse Outcome in Breast Cancer Patients von Piersma, Djura, Berns, Els M. J. J., Verhoef-Post, Miriam, Uitterlinden, Andre G., Braakman, Ineke, Pols, Huibert A. P., Themmen, Axel P. N.

Volltext

Abstract P3-06-01: Hotspot mutations in PIK3CA are predictive for treatment outcome on aromatase inhibitors but not for tamoxifen von Ramirez, Ardila DE, Helmijr, JC, Lurkin, I, Look, M, Ruigrok-Ritstier, K, Simon, I, Van Laere, S, Sweep, F, Span, P, Linn, S, Foekens, J, Sleijfer, S, Berns, EMJJ, Jansen, MPHM

Volltext

Abstract PD01-03: Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment von Beelen, KJ, Opdam, M, Severson, TM, Koornstra, RHT, Vincent, A, Wesseling, J, Muris, JJ, Berns, EMJJ, Vermorken, JB, van Diest, PJ, Linn, SC

Volltext

Abstract P6-04-08: FOXA1 expression: regulated by EZH2 and associated with favorable outcome to tamoxifen in advanced breast cancer von Reijm, EA, Helmijr, JCA, Soler, CMJ, Beekman, R, Gerritse, FL, Prager-van, der Smissen WJC, Ruigrok-Ritstier, K, van IJcken, WFJ, Stevens, MG, Smid, M, Look, MP, Meijer, ME, Sieuwerts, AM, Sleijfer, S, Foekens, JA, Berns, EMJJ, Jansen, MPHM

Volltext

The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine von Foekens, John A., Wang, Yixin, Martens, John W.M., Berns, Els M.J.J., Klijn, Jan G.M.

Volltext

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer von BERNS, E. M. J. J, FOEKENS, J. A, CORNELISSE, C, CLAASSEN, C. J. C, PORTENGEN, H, BAKKER, B, KLIJN, J. G. M, VOSSEN, R, LOOK, M. P, DEVILEE, P, HENZEN-LOGMANS, S. C, VAN STAVEREN, I. L, VAN PUTTEN, W. L. J, INGANÄS, M, MEIJER-VAN GELDER, M. E

Volltext

Abstract P4-07-01: Correlation of Breast Cancer Susceptibility Loci with Patient Characteristics, Metastasis-Free Survival and Expression of the Nearest Genes von Riaz, M, Berns, EMJJ, Sieuwerts, AM, Ruigrok-Ritstier, K, de Weerd, V, Uitterlinden, AG, Look, MP, Klijn, JGM, Sleijfer, S, Foekens, JA, Martens, JWM

Volltext

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2 von Schuyer, M, Burg, M E L van der, Henzen-Logmans, S C, Fieret, J H, Klijn, J G M, Look, M P, Foekens, J A, Stoter, G, Berns, E M J J

Volltext

Combined Vascular Endothelial Growth Factor and TP53 Status Predicts Poor Response to Tamoxifen Therapy in Estrogen Receptor-positive Advanced Breast Cancer von BERNS, Els M. J. J, KLIJN, Jan G. M, BAKKER, Bert, SWEEP, Fred C. G. J, FOEKENS, John A, LOOK, Maxime P, GREBENCHTCHIKOV, Nicolai, VOSSEN, Rolf, PETERS, Harry, GEURTS-MOESPOT, Anneke, PORTENGEN, Henk, VAN STAVEREN, Iris L, MEIJER-VAN GELDER, Marion E

Volltext

Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer von Powell, Brenda L., van Staveren, Iris L., Roosken, Paul, Grieu, Fabienne, Berns, Els M.J.J., Iacopetta, Barry

Volltext

Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865) von Green, J.A., Berns, E.M.J.J., Coens, C., van Luijk, I., Thompson-Hehir, J., van Diest, P., Verheijen, R.H.M., van de Vijver, M., van Dam, P., Kenter, G.G., Tjalma, W., Ewing, P.C., Teodorovic, I., Vergote, I., van der Burg, M.E.L.

Volltext

Tamoxifen resistance in breast cancer : Elucidating mechanisms von DORSSERS, Lambert C. J, VAN DER FLIER, Silvia, BRINKMAN, Arend, VAN AGTHOVEN, Ton, VELDSCHOLTE, Jos, BERNS, Els M. J. J, KLIJN, Jan G. M, BEEX, Louk V. A. M, FOEKENS, John A

Volltext

Is TP53 dysfunction required for BRCA1-associated carcinogenesis? von Schuyer, Monique, Berns, Els M.J.J.

Volltext